Characteristics, resource utilization and safety profile of patients prescribed with neuropathic pain treatments: a real-world evidence study on general practices in Europe – the role of the lidocaine 5% medicated plaster

References

• National Institute for Health and Care Excellence. Neuropathic pain in adults: pharmacological management in non-specialist settings. Available at: http://guidance.nice.org.uk/CG173 [Last accessed November 2013]
   Google Scholar
• Kremer M, Yalcin I, Nexon L et al. The antiallodynic action of pregabalin in neuropathic pain is independent from the opioid system. Mol Pain 2016;12:1-12
   Web of Science ®Google Scholar
• Beniczky S, Tajti J, Tímea Varga E, et al. Evidence-based pharmacological treatment of neuropathic pain syndromes. J Neural Transm 2005;12:735-49
   Web of Science ®Google Scholar
• Ney JP, Devine EB, Watanabe JH, et al. Comparative efficacy of oral pharmaceuticals for the treatment of chronic peripheral neuropathic pain: meta-analysis and indirect treatment comparisons. Pain Med 2013;14:706-19
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study” – a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain 2013;154:2616-25
   PubMed Web of Science ®Google Scholar
• Navez ML, Monella C, Bösl I, et al. 5% lidocaine medicated plaster for the treatment of postherpetic neuralgia: a review of the clinical safety and tolerability. Pain Ther 2015;4:1-15
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(3Suppl):S3-S14
   Web of Science ®Google Scholar
• Miskovic M. Comparison of tolerance of venlafaxine, paroxetine and amitriptyline in depression therapy. Med Arch 2015;69:107-9
   PubMedGoogle Scholar
• Oster G, Berger A, Dukes E, et al. Use of potentially inappropriate pain-related medications in older adults with painful neuropathic disorders. Am J Geriatr Pharmacother 2004;2:163-70
   PubMedGoogle Scholar
• Cowen PJ, Ogilvie AD, Gama J. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression. Curr Med Res Opin 2005;21:345-56
   PubMed Web of Science ®Google Scholar
• Yasuda H, Hotta N, Kasuga M. Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: results from a randomized, 52-week, open-label study. J Diabetes Investig 2016;7:100-8
   PubMed Web of Science ®Google Scholar
• Allegri M, Baron R, Hans G, et al. A pharmacological treatment algorithm for localized neuropathic pain. Curr Med Res Opin 2016;32:377-84
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65:39-44
   PubMed Web of Science ®Google Scholar
• Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999;80:533-8
   PubMed Web of Science ®Google Scholar
• Baron R, Mayoral V, Leijon G, et al. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open label, non-inferiority two-stage RCT study. Curr Med Res Opin 2009;25:1663-76
   PubMed Web of Science ®Google Scholar
• Binder A, Bruxelle J, Rogers P, et al. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig 2009;29:393-408
   PubMed Web of Science ®Google Scholar
• Rehm S, Binder A, Baron R. Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr Med Res Opin 2010;26:1607-19
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations. Lancet Neurol 2015;14:162-73
   PubMed Web of Science ®Google Scholar
• Liedgens H, Obradovic M, De Courcy J, et al. A burden of illness study for neuropathic pain in Europe. Clinicoecon Outcomes Res 2016;8:113-26
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-e88
   PubMed Web of Science ®Google Scholar
• Barkin RL. The pharmacology of topical analgesics. Postgrad Med 2013;125(4Suppl1):7-18
   Google Scholar
• Cotté FE, Benhaddi H, Duprat-Lomon I, et al. Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries. Clin Ther 2014;36:1160-8
   PubMed Web of Science ®Google Scholar
• Levi M, Rosselli M, Simonetti M, et al. Epidemiology of iron deficiency anaemia in four European countries: a population-based study in primary care. Eur J Haematol 2016;97:583-93
   PubMed Web of Science ®Google Scholar
• Maina G, Ripellino C. The risk of metabolic disorders in patients treated with asenapine or olanzapine: a study conducted on real-world data in Italy and Spain. Expert Opin Drug Saf 2014;13:1149-54
   PubMed Web of Science ®Google Scholar
• Katz P, Vailati S. Indagine sull’utilizzo di ibuprofene arginina, ketoprofene lisina e diclofenac per la terapia del dolore da osteoartrosi, artrite, dolore lombare, cefalea e dismenorrea, presso l’ambulatorio del medico di medicina generale. Rivista SIMG 2010;2:28-32
   Google Scholar
• Cepeda MS, Boston R, Farrar JT, et al. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 2003;158:280-7
   PubMed Web of Science ®Google Scholar
• Fogliardi A, Brunori C. Esperienza con lidocaina cerotto 5% nel trattamento del dolore neuropatico localizzato. Minerva Med 2013;104:631-7
   PubMed Web of Science ®Google Scholar
• Berger A, Toelle T, Sadosky A, et al. Clinical and economic characteristics of patients with painful neuropathic disorders in Germany. Pain Practice 2009;9:8-17
   PubMed Web of Science ®Google Scholar
• Hall GC, Carroll D, Parry D, et al. Epidemiology and treatment of neuropathic pain: The UK primary care perspective. Pain 2006;122:156-62
   PubMed Web of Science ®Google Scholar
• Gore M, Dukes E, Rowbotham D, et al. Prevalence of contraindicated medical conditions and use of precluded medications in patients with painful neuropathic disorders prescribed amitriptyline. Pain Practice 2006;6:265-72
   PubMedGoogle Scholar
• Berger A, Sadosky A, Dukes E, et al. Use of pregabalin in patients with painful neuropathic disorders under the care of general practitioners in the UK. Pain Practice 2008;9:18-34
   PubMed Web of Science ®Google Scholar
• Berger A, Sadosky A, Dukes E, et al. Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders in UK general practice: a retrospective cohort study. BMC Neurology 2012;12:1-13
   PubMed Web of Science ®Google Scholar
• Glynn LG, Valderas JM, Healy P, et al. The prevalence of multimorbidity in primary care and its effect on health care utilization and cost. Family Pract 2011;28:516-23
   PubMed Web of Science ®Google Scholar
• Moffat K, Mercer SW. Challenges of managing people with multimorbidity in today’s healthcare systems. BMC Fam Pract 2015;16:129
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Hillert J, Butzkueven H. The importance of collecting structured clinical information on multiple sclerosis. BMC Med 2016;14:81
   PubMed Web of Science ®Google Scholar